This article reviews presentations that took place at the 64th American Society of Hematology (ASH) Annual Meeting, between 10th–13th December 2022, in New Orleans, Louisiana, USA. Exploring gene therapy for the treatment of haemophilia A and B by highlighting key updates from clinical trials and pre-clinical data, this congress review discusses recombinant adeno-associated virus (rAAV)-based gene therapy products and non-viral gene therapy strategies in haemophilia treatment, and details the translation from research into clinical practice.
EMJ Hematology 11 [Supplement 1] . 2023
February 2023
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given